<!DOCTYPE html>
<html  >
<head>
  <!-- Site made with Mobirise Website Builder v5.3.0, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v5.3.0, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
  <link rel="shortcut icon" href="assets/images/logo-1-96x83.png" type="image/x-icon">
  <meta name="description" content="">
  
  
  <title>Home</title>
  <link rel="stylesheet" href="assets/web/assets/mobirise-icons2/mobirise2.css">
  <link rel="stylesheet" href="assets/web/assets/mobirise-icons/mobirise-icons.css">
  <link rel="stylesheet" href="assets/tether/tether.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-grid.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-reboot.min.css">
  <link rel="stylesheet" href="assets/dropdown/css/style.css">
  <link rel="stylesheet" href="assets/socicon/css/styles.css">
  <link rel="stylesheet" href="assets/theme/css/style.css">
  <link rel="preload" as="style" href="assets/mobirise/css/mbr-additional.css"><link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
  
</head>
<body>
  
  <section class="menu menu1 cid-srKtGrqIa9" once="menu" id="menu1-e">
    

    <nav class="navbar navbar-dropdown navbar-fixed-top navbar-expand-lg">
        <div class="container-fluid">
            <div class="navbar-brand">
                <span class="navbar-logo">
                    
                        <img src="assets/images/logo-1-96x83.png" alt="Mobirise" style="height: 3rem;">
                    
                </span>
                <span class="navbar-caption-wrap"><a class="navbar-caption text-secondary text-primary display-7" href="index.html">CardioRISC</a></span>
            </div>
            <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation">
                <div class="hamburger">
                    <span></span>
                    <span></span>
                    <span></span>
                    <span></span>
                </div>
            </button>
            <div class="collapse navbar-collapse" id="navbarSupportedContent">
                <ul class="navbar-nav nav-dropdown nav-right" data-app-modern-menu="true"><li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="aboutus.html">
                            About us</a></li>
                    <li class="nav-item dropdown"><a class="nav-link link text-secondary text-primary dropdown-toggle display-4" href="#" data-toggle="dropdown-submenu" aria-expanded="false">
                            Our Staff</a><div class="dropdown-menu"><a class="text-secondary text-primary dropdown-item display-4" href="ourteam.html">Prof Tony Bjourson</a><div class="dropdown"><a class="text-secondary text-primary dropdown-item dropdown-toggle display-4" href="#" aria-expanded="false" data-toggle="dropdown-submenu">Dr Raymond Bond</a><div class="dropdown-menu dropdown-submenu"><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">New Item</a></div></div><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Adam Canning</a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Catriona Kelly</a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Roisin McAllister<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Victoria McGilligan<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Monica Monaghan<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Prof Aaron Peace<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Taranjit Singh Rai<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr James Shand<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Divyesh Sharma<br></a><a class="text-secondary text-primary dropdown-item display-4" href="#" aria-expanded="true">Dr Steven Watterson<br></a></div></li><li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="#" aria-expanded="true">
                            Our Students</a></li>
                    <li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="publications.html">Publications</a>
                    </li><li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="educationtraining.html">Education &amp; Career<br>&nbsp; &nbsp; &nbsp;Opportunities</a></li><li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="https://twitter.com/cardiorisc" target="_blank"><span class="socicon socicon-twitter mbr-iconfont mbr-iconfont-btn" style="color: rgb(34, 165, 229);"></span></a></li><li class="nav-item"><a class="nav-link link text-secondary text-primary display-4" href="contactus.html">Contact Us</a></li></ul>
                
                
            </div>
        </div>
    </nav>
</section>

<section class="features11 cid-ss8STNqive" id="features12-17">

    
    
    <div class="container">
        <div class="row align-items-center">
            <div class="col-12 col-lg">
                <div class="card-wrapper">
                    <div class="card-box">
                        
                        <p class="mbr-text mbr-fonts-style mb-4 display-7">
                            The <strong>Cardiovascular Research and Improvement Science Centre (CardioRISC)</strong> is a multidisciplinary collaboration between <a href="https://www.ulster.ac.uk/cardiovascular" class="text-primary" target="_blank">Ulster University</a> and the <a href="https://westerntrust.hscni.net/" class="text-primary" target="_blank">Western Health and Social Care Trust</a>. We bring together the key areas of Personalised Medicine, Digital Health and Improvement Science.</p>
                        
                        
                    </div>
                </div>
            </div>
            <div class="col-12 col-lg-4 md-pb">
                <div class="image-wrapper">
                    <img src="assets/images/logo-428x372.png" alt="Mobirise">
                </div>
            </div>
        </div>
    </div>
</section>

<section class="content13 cid-srKwqNhhbl" id="content13-k">
    
    
    <div class="container">
        <div class="row justify-content-center">
            <div class="col-md-12 col-lg-12">
                <h3 class="mbr-section-title mbr-fonts-style mb-4 display-7">
                    <strong>We are working to</strong></h3>
            </div>
        </div>
        <div class="row justify-content-center">
            <div class="col-md-12 col-lg-12">
                <div class="row justify-content-center">
                    <div class="col-12 col-lg-6">
                        <ul class="list mbr-fonts-style display-7">
                            <li>Better understand the mechanisms of cardiovascular disease&nbsp;
</li><li>Better understand atrial fibrillation, focussing on cellular senescence (aging)&nbsp; <strong>
</strong></li><li>Develop novel biomarkers as diagnostic and prognostic indicators of cardiovascular risk in ischaemic heart disease<strong>&nbsp;
</strong></li><li>Develop new clinical pathways in atrial fibrillation and heart failure by integrating digital and immersive technology&nbsp;
</li>
                        </ul>
                    </div>
                    <div class="col-12 col-lg-6">
                        <ul class="list mbr-fonts-style display-7">
                            <li><span style="font-size: 1.2rem;">Further develop our innovative anti inflammatory therapeutic pipelines for coronary artery disease and atrial fibrillation </span></li><li><span style="font-size: 1.2rem;">Employ artificial intelligence to improve cardiovascular diagnostic imaging and our understanding of molecular changes in cardiovascular disease.</span><br></li><li>Use data analytics and digital technology to improve clinical care pathways in cardiology&nbsp;</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
    </div>
</section>

<section class="content16 cid-srLclXMpMO" id="content16-r">

    

    
    <div class="container">
        <div class="row justify-content-center">
            <div class="col-12 col-md-12">
                <div class="mbr-section-head align-center mb-4">
                    <h3 class="mbr-section-title mb-0 mbr-fonts-style display-7">
                        <strong>Select Publications</strong></h3>
                    
                </div>
                <div id="bootstrap-accordion_3" class="panel-group accordionStyles accordion" role="tablist" aria-multiselectable="true">
                    <div class="card mb-3">
                        <div class="card-header" role="tab" id="headingOne">
                            <a role="button" class="panel-title collapsed" data-toggle="collapse" data-core="" href="#collapse1_3" aria-expanded="false" aria-controls="collapse1">
                                <h6 class="panel-title-edit mbr-fonts-style mb-0 display-7"><strong>Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing‐induced heart failure </strong>Gomez N, Touihri K, Matheeussen V, Da Costa AM, Mahmoudabady M, Mathieu M, Baerts L, Peace A, Lybaert P, Scharpé S, De Meester I, European Journal of Heart Failure. 2012 Jan;14(1):14-21.&nbsp;&nbsp;</h6>
                                <span class="sign mbr-iconfont mbri-arrow-down"></span>
                            </a>
                        </div>
                        <div id="collapse1_3" class="panel-collapse noScroll collapse" role="tabpanel" aria-labelledby="headingOne" data-parent="#bootstrap-accordion_3">
                            <div class="panel-body">
                                <p class="mbr-fonts-style panel-text display-4">Aims
<br>Recent studies indicate that brain natriuretic peptide (BNP1–32) may be truncated into BNP3–32 by dipeptidyl peptidase IV (DPP4) and that BNP3–32 has reduced biological activities compared with BNP1–32. We investigated if DPP4 contributes to the cardiorenal alterations and to the attenuated response to BNP seen in heart failure.
<br>
<br>Methods and results
<br>Haemodynamic and renal assessment was performed in 12 pigs at baseline, 4 weeks after pacing‐induced heart failure, and during BNP infusion. They were randomized to either placebo or treatment with a DPP4 inhibitor, sitagliptin. After 4 weeks of pacing, heart rate was reduced compared with baseline in the sitagliptin group (60 ± 2 vs. 95 ± 16 b.p.m., P &lt; 0.01), and an increase in stroke volume was observed in the sitagliptin group compared with placebo (+24 ± 6% vs. –17 ± 7%, P &lt; 0.01). Glomerular filtration rate declined at week 4 compared with baseline in the placebo group (1.3 ± 0.4 vs. 2.3 ± 0.3 mL/kg/min, P &lt; 0.01) but remained preserved in the sitagliptin group [1.8 ± 0.2 vs. 2.0 ± 0.3 mL/kg/min, P = NS (non‐significant)]. In the sitagliptin group, BNP infusion improved end‐systolic elastance (68 ± 5 vs. 31 ± 4 mmHg/kg/mL, P &lt; 0.05), ventricular–arterial coupling, and mechanical efficiency. Compared with controls (n = 6), myocardial gene expression of BNP, interleukin‐6, Na+–Ca2+ exchanger, and calmodulin was up‐regulated in the placebo group, but not in the sitagliptin group.
<br>
<br>Conclusion
<br>In pacing‐induced heart failure, DPP4 inhibition preserves the glomerular filtration rate, modulates stroke volume and heart rate, and potentiates the positive inotropic effect of exogenous BNP at no energy expense.<br><br>&nbsp;https://doi.org/10.1093/eurjhf/hfr146<br></p>
                            </div>
                        </div>
                    </div>
                    <div class="card mb-3">
                        <div class="card-header" role="tab" id="headingOne">
                            <a role="button" class="panel-title collapsed" data-toggle="collapse" data-core="" href="#collapse2_3" aria-expanded="false" aria-controls="collapse2">
                                <h6 class="panel-title-edit mbr-fonts-style mb-0 display-7"><strong>Long-term clinical outcome after fractional flow reserve–guided percutaneous coronary revascularization in patients with small-vessel disease&nbsp;</strong>Puymirat E, Peace A, Mangiacapra F, Conte M, Ntarladimas Y, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E. Circulation: Cardiovascular Interventions. 2012 Feb;5(1):62-8.&nbsp;<strong> &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></h6>
                                <span class="sign mbr-iconfont mbri-arrow-down"></span>
                            </a>
                        </div>
                        <div id="collapse2_3" class="panel-collapse noScroll collapse" role="tabpanel" aria-labelledby="headingOne" data-parent="#bootstrap-accordion_3">
                            <div class="panel-body">
                                <p class="mbr-fonts-style panel-text display-4">Background<br>Small coronary vessels supply small myocardial territories. The clinical significance of small-vessel stenoses is therefore questionable. Moreover, percutaneous coronary intervention (PCI) of nonfunctionally significant lesions does not improve clinical outcome and might be associated with potential procedural or stent related risks. The aim of this study was to assess the clinical outcome of fractional flow reserve (FFR)-guided PCI in the treatment of small coronary vessel lesions as compared with an angio-guided PCI.
<br>
<br>Methods and Results<br>From January 2004 to December 2008, all patients treated with PCI for stable or unstable angina in small native coronary vessels (reference vessel diameter and stent size &lt;3 mm) were retrospectively analyzed. Patients were divided into angio-guided and an FFR-guided PCI groups. A total of 717 patients were enrolled (495 angio-guided, 222 FFR-guided). End points were death, nonfatal myocardial infarction (MI), combined death or nonfatal MI, target vessel revascularization (TVR), and procedure costs. Major adverse cardiac events (MACE) were defined as death, nonfatal MI, and TVR. Clinical follow-up was obtained in 97.5% (median follow-up: 3.3 [from 0.01–5] years) of the patients. Seventy-eight patients (35%) had a significant FFR (&lt;0.80) and underwent PCI. Using a propensity score adjusted Cox analysis, patients treated with FFR-guided PCI had significantly lower combined death or nonfatal MI (hazard ratio [HR], 0.413; 95% confidence interval [CI], 0.227–0.750; P=0.004), nonfatal MI (HR, 0.063; 95% CI, 0.009–0.462; P=0.007), TVR (HR, 0.517; 95% CI, 0.323–0.826; P=0.006), and MACE (HR, 0.458; 95% CI, 0.310–0.679; P&lt;0.001). No difference was observed in mortality alone (HR, 0.684; 95% CI, 0.355–1.316; P=0.255). Procedure costs were also reduced in the FFR guided strategy (3253±102 Euros versus 4714±37 Euros, P&lt;0.0001).
<br>
<br>Conclusions<br>FFR-guided PCI of small coronary arteries is safe and results in better clinical outcomes when compared with an angio-guided PCI.<br><br>https://doi.org/10.1161/CIRCINTERVENTIONS.111.966937<br></p>
                            </div>
                        </div>
                    </div>
                    <div class="card mb-3">
                        <div class="card-header" role="tab" id="headingOne">
                            <a role="button" class="panel-title collapsed" data-toggle="collapse" data-core="" href="#collapse3_3" aria-expanded="false" aria-controls="collapse3">
                                <h6 class="panel-title-edit mbr-fonts-style mb-0 display-7"><strong>Lysosome-mediated processing of chromatin in senescence </strong>Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, Shah PP, Hewitt G, Korolchuk VI, Passos JF, Wu H.&nbsp; Journal of Cell Biology. 2013 Jul 8;202(1):129-43.</h6>
                                <span class="sign mbr-iconfont mbri-arrow-down"></span>
                            </a>
                        </div>
                        <div id="collapse3_3" class="panel-collapse noScroll collapse" role="tabpanel" aria-labelledby="headingOne" data-parent="#bootstrap-accordion_3">
                            <div class="panel-body">
                                <p class="mbr-fonts-style panel-text display-4">
                                    Cellular senescence is a stable proliferation arrest, a potent tumor suppressor mechanism, and a likely contributor to tissue aging. Cellular senescence involves extensive cellular remodeling, including of chromatin structure. Autophagy and lysosomes are important for recycling of cellular constituents and cell remodeling. Here we show that an autophagy/lysosomal pathway processes chromatin in senescent cells. In senescent cells, lamin A/C–negative, but strongly γ-H2AX–positive and H3K27me3-positive, cytoplasmic chromatin fragments (CCFs) budded off nuclei, and this was associated with lamin B1 down-regulation and the loss of nuclear envelope integrity. In the cytoplasm, CCFs were targeted by the autophagy machinery. Senescent cells exhibited markers of lysosomal-mediated proteolytic processing of histones and were progressively depleted of total histone content in a lysosome-dependent manner. In vivo, depletion of histones correlated with nevus maturation, an established histopathologic parameter associated with proliferation arrest and clinical benignancy. We conclude that senescent cells process their chromatin via an autophagy/lysosomal pathway and that this might contribute to stability of senescence and tumor suppression.<br><br>https://doi.org/10.1083/jcb.201212110<br></p>
                            </div>
                        </div>
                    </div>
                    <div class="card mb-3">
                        <div class="card-header" role="tab" id="headingOne">
                            <a role="button" class="panel-title collapsed" data-toggle="collapse" data-core="" href="#collapse4_3" aria-expanded="false" aria-controls="collapse4">
                                <h6 class="panel-title-edit mbr-fonts-style mb-0 display-7"><strong>Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape </strong>Shah PP, Donahue G, Otte GL, Capell BC, Nelson DM, Cao K, Aggarwala V, Cruickshanks HA, Rai TS, McBryan T, Gregory BD. Genes &amp; development. 2013 Aug 15;27(16):1787-99.</h6>
                                <span class="sign mbr-iconfont mbri-arrow-down"></span>
                            </a>
                        </div>
                        <div id="collapse4_3" class="panel-collapse noScroll collapse" role="tabpanel" aria-labelledby="headingOne" data-parent="#bootstrap-accordion_3">
                            <div class="panel-body">
                                <p class="mbr-fonts-style panel-text display-4">
                                    Senescence is a stable proliferation arrest, associated with an altered secretory pathway, thought to promote tumor suppression and tissue aging. While chromatin regulation and lamin B1 down-regulation have been implicated as senescence effectors, functional interactions between them are poorly understood. We compared genome-wide Lys4 trimethylation on histone H3 (H3K4me3) and H3K27me3 distributions between proliferating and senescent human cells and found dramatic differences in senescence, including large-scale domains of H3K4me3- and H3K27me3-enriched “mesas” and H3K27me3-depleted “canyons.” Mesas form at lamin B1-associated domains (LADs) in replicative senescence and oncogene-induced senescence and overlap DNA hypomethylation regions in cancer, suggesting that pre-malignant senescent chromatin changes foreshadow epigenetic cancer changes. Hutchinson-Gilford progeria syndrome fibroblasts (mutant lamin A) also show evidence of H3K4me3 mesas, suggesting a link between premature chromatin changes and accelerated cell senescence. Canyons mostly form between LADs and are enriched in genes and enhancers. H3K27me3 loss is correlated with up-regulation of key senescence genes, indicating a link between global chromatin changes and local gene expression regulation. Lamin B1 reduction in proliferating cells triggers senescence and formation of mesas and canyons. Our data illustrate profound chromatin reorganization during senescence and suggest that lamin B1 down-regulation in senescence is a key trigger of global and local chromatin changes that impact gene expression, aging, and cancer.<br><br>https://doi.org/10.1101/gad.223834.113</p>
                            </div>
                        </div>
                    </div>
                    <div class="card mb-3">
                        <div class="card-header" role="tab" id="headingOne">
                            <a role="button" class="panel-title collapsed" data-toggle="collapse" data-core="" href="#collapse5_3" aria-expanded="false" aria-controls="collapse5">
                                <h6 class="panel-title-edit mbr-fonts-style mb-0 display-7"><strong>Computational modelling of atherosclerosis  </strong>A Parton, V McGilligan, M O’Kane, FR Baldrick, S Watterson , Briefings in Bioinformatics 17(4), 562-575 (2016)&nbsp;</h6>
                                <span class="sign mbr-iconfont mbri-arrow-down"></span>
                            </a>
                        </div>
                        <div id="collapse5_3" class="panel-collapse noScroll collapse" role="tabpanel" aria-labelledby="headingOne" data-parent="#bootstrap-accordion_3">
                            <div class="panel-body">
                                <p class="mbr-fonts-style panel-text display-4">Atherosclerosis is one of the principle pathologies of cardiovascular disease with blood cholesterol a significant risk factor. The World Health Organization estimates that approximately 2.5 million deaths occur annually because of the risk from elevated cholesterol, with 39% of adults worldwide at future risk. Atherosclerosis emerges from the combination of many dynamical factors, including haemodynamics, endothelial damage, innate immunity and sterol biochemistry. Despite its significance to public health, the dynamics that drive atherosclerosis remain poorly understood. As a disease that depends on multiple factors operating on different length scales, the natural framework to apply to atherosclerosis is mathematical and computational modelling. A computational model provides an integrated description of the disease and serves as an in silico experimental system from which we can learn about the disease and develop therapeutic hypotheses. Although the work completed in this area to date has been limited, there are clear signs that interest is growing and that a nascent field is establishing itself. This article discusses the current state of modelling in this area, bringing together many recent results for the first time. We review the work that has been done, discuss its scope and highlight the gaps in our understanding that could yield future opportunities. 
<br>
<br>https://doi.org/10.1093/bib/bbv081</p>
                            </div>
                        </div>
                    </div>
                    
                </div>
            </div>
        </div>
    </div>
</section><section style="background-color: #fff; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Roboto', 'Helvetica Neue', Arial, sans-serif; color:#aaa; font-size:12px; padding: 0; align-items: center; display: flex;"><a href="https://mobirise.site/u" style="flex: 1 1; height: 3rem; padding-left: 1rem;"></a><p style="flex: 0 0 auto; margin:0; padding-right:1rem;"><a href="https://mobirise.site/s" style="color:#aaa;">Website</a> was designed with Mobirise website theme</p></section><script src="assets/web/assets/jquery/jquery.min.js"></script>  <script src="assets/popper/popper.min.js"></script>  <script src="assets/tether/tether.min.js"></script>  <script src="assets/bootstrap/js/bootstrap.min.js"></script>  <script src="assets/smoothscroll/smooth-scroll.js"></script>  <script src="assets/dropdown/js/nav-dropdown.js"></script>  <script src="assets/dropdown/js/navbar-dropdown.js"></script>  <script src="assets/touchswipe/jquery.touch-swipe.min.js"></script>  <script src="assets/mbr-switch-arrow/mbr-switch-arrow.js"></script>  <script src="assets/theme/js/script.js"></script>  
  
  
</body>
</html>